Reyataz (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, 'Reyataz (HIV) - Forecast and Market Analysis to 2022'. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.Reyataz (atazanavir sulfate/ATV) is a PI indicated for use in combination with other antiretroviral agents for the treatment of HIV infection in patients over six years of age (Reyataz prescribing information, 2012; Reyataz Summary of Product Characteristics, 2012). Reyataz's mechanism of action involves inhibiting the HIV protease (i.e., blocks the cleavage of the Gag and Gag-Pol polyproteins), which disrupts the maturation process of the virus resulting in the release of immature, non-infectious HIV virions. Scope - Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on Reyataz including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for Reyataz for the top nine countries from 2012 to 2022.- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for HIV- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of Reyataz performance- Obtain sales forecast for Reyataz from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Reyataz (HIV) - Forecast and Market Analysis to 2022
Published on January 2013
Report Summary
Reyataz (HIV) - Forecast and Market Analysis to 2022
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, 'Reyataz (HIV) - Forecast and Market Analysis to 2022'.
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the
advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition
for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also
decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved
multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the
emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst
physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.
Reyataz (atazanavir sulfate/ATV) is a PI indicated for use in combination with other antiretroviral agents for the treatment of HIV
infection in patients over six years of age (Reyataz prescribing information, 2012; Reyataz Summary of Product Characteristics,
2012). Reyataz's mechanism of action involves inhibiting the HIV protease (i.e., blocks the cleavage of the Gag and Gag-Pol
polyproteins), which disrupts the maturation process of the virus resulting in the release of immature, non-infectious HIV virions.
Scope
- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on Reyataz including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Reyataz for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Reyataz performance
- Obtain sales forecast for Reyataz from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan,
Brazil and China)
Table of Content
1 Table of Contents
Reyataz (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Reyataz (atazanavir) 23
6.1 Overview 23
6.2 Efficacy 24
6.3 Safety 25
6.4 SWOT Analysis 25
6.5 Forecast 27
7 Appendix 28
7.1 Bibliography 28
7.2 Abbreviations 30
7.3 Methodology 32
7.4 Forecasting Methodology 32
7.4.1 HIV Prevalence 32
7.4.2 Percent Drug-Treated Patients 32
7.4.3 General Pricing Assumptions 33
7.4.4 Individual Drug Assumptions 34
7.4.5 Generic Erosion 34
7.5 Physicians and Specialists Included in this Study 35
7.5.1 Survery of Prescribing Physicians 36
7.6 About the Authors 36
7.6.1 Authors 36
7.6.2 Global Head of Healthcare 37
7.7 About GlobalData 38
7.8 Contact Us 38
7.9 Disclaimer 38
List of Tables
Reyataz (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile ' Reyataz 24
Table 6: Reyataz SWOT Analysis, 2012 26
Table 7: Global Sales Forecasts ($m) for Reyataz, 2012-2022 27
Table 8: Physicians Surveyed, By Country 36
List of Figures
Figure 1: HIV Lifecycle 11
Reyataz (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Reyataz (HIV) - Forecast and Market Analysis to 2022
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 6 995.00 Quantity: _____
Site License--USD 13 990.00 Quantity: _____
Corporate License--USD 20 985.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Reyataz (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Reyataz (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 5/5